ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2196

Treprostinil Use in Malignant Atrophic Papulosis (Köhlmeier-Degos Disease): Review of Worldwide Experience to Date

Lee S. Shapiro1,2, Aixa Toledo-Garcia1,3 and Jessica F. Farrell1,4,5, 1Steffens Scleroderma Center, Saratoga Springs, NY, 2Albany Medical College, Albany, NY, 3Rheumatology, The Center for Rheumatology, Albany, NY, 4Pharmacy Practice, Albany College of Pharmacy & Health Sciences, Albany, NY, 5The Center for Rheumatology, Albany, NY

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Degos Disease, scleroderma-like conditions and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Miscellaneous Rheumatic and Inflammatory Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose

Malignant atrophic papulosis (MAP) is a rare thrombo-occlusive vasculopathy that presents with cutaneous only lesions but can progress after months or years to rapidly fatal systemic involvement.   Until the very recent past, there were no reports of effective treatment of the systemic disease.  A recent publication described successful use of trepostinil, a prostacyclin analog, in treatment of systemic MAP and in MAP-scleroderma-SLE overlap. 

Methods

We performed a retrospective analysis of six patients using data collected from treating physicians worldwide through personal communications and our own experience. We also employed PUBMED for a literature search, which yielded 200 articles, using the keywords malignant atrophic papulosis and Degos disease. We evaluated outcomes of six MAP patients who were treated with treprostinil to identify discriminating factors between survivors and non-survivors.

Results

Among the six treprostinil MAP treated patients we know four are alive.  Our first treprostinil treated patient was a female with scleroderma/SLE overlap who developed MAP lesions without systemic MAP involvement. As a result of pulmonary hypertension she was started on treprostinil. Cutaneous lesions subsequently resolved. We then treated a primary MAP male who had progressive CNS disease despite ongoing therapy with eculizumab. Within months after treprostinil was started MRI showed resolution of the lesions. Another male on eculizumab with disease progression was started on treprostinil with resolution of symptoms. The fourth patient was a female with biopsy proven MAP who already had CNS involvement with loss of vision in the right eye that led to enucleation.  Treprostinil was started with temporary stabilization of symptoms. In the fifth patient, treprostinil was started after severe systemic involvement had taken place. She had GI perforations and CNS involvement which led to death. Eculizumab was not the first line therapy in patients four and five.  Lastly, through a literature search we found a sixth patient who was a female on treprostinil for pulmonary hypertension related to systemic sclerosis.  She then developed a restricted form of MAP while on treprostinil and is possibly alive, making a total of five patients alive today.

Conclusion

MAP is a rapidly fatal systemic disorder with a life expectancy of less than one year after development of visceral involvement.   After comprehensive review of treprostinil use for MAP, we found the majority of patients treated (4/5) are still alive up to 42 months after initiation of therapy.  All survivors with systemic disease are on dual therapy with eculizumab.  The first patient with cutaneous MAP and scleroderma/SLE overlap had resolution of skin lesions on treprostinil alone.  Patient six developed a restricted form of MAP while on treprostinil leading the authors to believe treprostinil limited the MAP vasculopathic process.  The efficacy of treprostinil in MAP may be related not only to antithrombotic and vasodilatory effects but also to its reported ability to increase the number of endothelial progenitor cells.


Disclosure:

L. S. Shapiro,
None;

A. Toledo-Garcia,
None;

J. F. Farrell,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treprostinil-use-in-malignant-atrophic-papulosis-kohlmeier-degos-disease-review-of-worldwide-experience-to-date/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology